BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

834 related articles for article (PubMed ID: 20106824)

  • 21. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
    Manno C; Torres DD; Rossini M; Pesce F; Schena FP
    Nephrol Dial Transplant; 2009 Dec; 24(12):3694-701. PubMed ID: 19628647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Very high doses of valsartan provide renoprotection independently of blood pressure in a type 2 diabetic nephropathy rat model.
    Tominaga N; Robert A; Izuhara Y; Ohtomo S; Dan T; Chihara K; Kurokawa K; Van Ypersele de Strihou C; Miyata T
    Nephrology (Carlton); 2009 Sep; 14(6):581-7. PubMed ID: 19712258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP.
    Pu Q; Brassard P; Javeshghani DM; Iglarz M; Webb RL; Amiri F; Schiffrin EL
    J Hypertens; 2008 Feb; 26(2):322-33. PubMed ID: 18192847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Renal hemodynamics and proteinuria in chronic glomerulonephritis treated with beta-receptor blockers or ace inhibitors].
    Erley CM; Berger ED; Heyne N; Klass M; Krämer D; Braun N; Wolf S; Risler T
    Dtsch Med Wochenschr; 1997 Aug; 122(31-32):953-8. PubMed ID: 9280714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Study of ACEI versus ARB in managing hypertensive overt diabetic nephropathy: long-term analysis.
    Ozturk S; Sar F; Bengi-Bozkurt O; Kazancioglu R
    Kidney Blood Press Res; 2009; 32(4):268-75. PubMed ID: 19776644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade.
    Ferrari P; Marti HP; Pfister M; Frey FJ
    J Hypertens; 2002 Jan; 20(1):125-30. PubMed ID: 11791035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term safety of high-dose angiotensin receptor blocker therapy in hypertensive patients with chronic kidney disease.
    Weinberg AJ; Zappe DH; Ramadugu R; Weinberg MS
    J Hypertens Suppl; 2006 Mar; 24(1):S95-9. PubMed ID: 16601581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
    Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency.
    Hou FF; Xie D; Zhang X; Chen PY; Zhang WR; Liang M; Guo ZJ; Jiang JP
    J Am Soc Nephrol; 2007 Jun; 18(6):1889-98. PubMed ID: 17494885
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of dual blockade of Renin-Angiotensin system on concentric left ventricular hypertrophy in essential hypertension: a randomized, controlled pilot study.
    Grandi AM; Solbiati F; Laurita E; Maresca AM; Nicolini E; Marchesi C; Gianni M; Guasti L; Venco A
    Am J Hypertens; 2008 Feb; 21(2):231-7. PubMed ID: 18174880
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Experience in the use of valsartan with the aim to inhibit progression of kidney failure in patients with chronic glomerulonephritis].
    Shvetsov MIu; Medvedeva TIu; Kozlovskaia NL; Miroshnichenko NG; Okonova EB; Shonichev DG; Rudenko TE; Stavrovskaia EV; Plieva OK
    Ter Arkh; 2001; 73(6):55-61. PubMed ID: 11521525
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
    Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Ghadanfar M; Weissbach N; Xiang Z; Armbrecht J; Pfeffer MA
    Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
    Han SW; Won YW; Yi JH; Kim HJ
    Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-grade albuminuria reduction with angiotensin II type 1 receptor blocker in renal transplant recipients.
    Uchida J; Machida Y; Iwai T; Iguchi T; Kamada Y; Naganuma T; Kumada N; Kim T; Kawashima H; Nakatani T
    J Nephrol; 2011; 24(4):515-21. PubMed ID: 21240871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial.
    Anand IS; Rector TS; Kuskowski M; Thomas S; Holwerda NJ; Cohn JN
    Circ Heart Fail; 2008 May; 1(1):34-42. PubMed ID: 19808268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
    Song JH; Cha SH; Lee HJ; Lee SW; Park GH; Lee SW; Kim MJ
    Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease.
    Homma K; Hayashi K; Kanda T; Yoshioka K; Takamatsu I; Tatematsu S; Kumagai H; Wakino S; Saruta T
    J Hum Hypertens; 2004 Dec; 18(12):879-84. PubMed ID: 15295613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy combined with diuretic therapy is associated with increased episodes of hypotension in noncardiac surgery.
    Kheterpal S; Khodaparast O; Shanks A; O'Reilly M; Tremper KK
    J Cardiothorac Vasc Anesth; 2008 Apr; 22(2):180-6. PubMed ID: 18375317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study.
    Andrés A; Morales E; Morales JM; Bosch I; Campo C; Ruilope LM;
    Transplant Proc; 2006 Oct; 38(8):2419-23. PubMed ID: 17097955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.